Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.31 USD
-0.28 (-3.26%)
Updated Sep 11, 2024 04:00 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 52 | 243 | 371 | 501 | 259 |
Receivables | 34 | 40 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 2 | 0 | 0 | 0 |
Other Current Assets | 6 | 10 | 12 | 21 | 14 |
Total Current Assets | 102 | 295 | 385 | 523 | 273 |
Net Property & Equipment | 4 | 6 | 54 | 51 | 54 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 7 | 4 | 2 | 2 |
Total Assets | 166 | 376 | 468 | 588 | 343 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 7 | 17 | 7 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 29 | 43 | 39 | 36 | 23 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 110 | 29 | 50 | 40 | 6 |
Total Current Liabilities | 142 | 79 | 106 | 83 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 38 | 77 | 56 | 28 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 39 | 36 | 2 | 2 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 265 | 250 | 189 | 126 | 52 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,870 | 1,822 | 1,745 | 1,587 | 1,109 |
Retained Earnings | -1,969 | -1,693 | -1,465 | -1,125 | -818 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -99 | 127 | 280 | 462 | 291 |
Total Liabilities & Shareholder's Equity | 166 | 376 | 468 | 588 | 343 |
Total Common Equity | -99 | 127 | 280 | 462 | 291 |
Shares Outstanding | 4.00 | 3.80 | 3.50 | 3.10 | 2.10 |
Book Value Per Share | -24.81 | 33.33 | 79.89 | 149.14 | 138.47 |
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 35 | 46 | 52 | 103 | 154 |
Receivables | 2 | 36 | 34 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 16 | 10 | 7 | 8 |
Other Current Assets | 6 | 8 | 6 | 9 | 10 |
Total Current Assets | 62 | 106 | 102 | 119 | 172 |
Net Property & Equipment | 2 | 3 | 4 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 5 | 6 | 7 |
Total Assets | 117 | 165 | 166 | 189 | 246 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 4 | 7 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 22 | 29 | 38 | 33 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 134 | 156 | 110 | 34 | 37 |
Total Current Liabilities | 148 | 181 | 142 | 79 | 75 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 38 | 74 | 76 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 41 | 39 | 38 | 37 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 228 | 264 | 265 | 240 | 239 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,909 | 1,903 | 1,870 | 1,858 | 1,847 |
Retained Earnings | -2,020 | -2,001 | -1,969 | -1,909 | -1,839 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -111 | -98 | -99 | -51 | 7 |
Total Liabilities & Shareholder's Equity | 117 | 165 | 166 | 189 | 246 |
Total Common Equity | -111 | -98 | -99 | -51 | 7 |
Shares Outstanding | 4.80 | 4.80 | 4.00 | 4.00 | 3.90 |
Book Value Per Share | -23.10 | -20.48 | -24.81 | -12.71 | 1.91 |